Table 21. Survival of Patients with CRC PC Treated by CRS and HIPEC and/or EPIC and/or SC: Summary of 76 Researches.

Author/ Years/ Country	1-yr SR (%)	2-yr SR (%)	3-yr SR (%)	4-yr SR (%)	5-yr SR (%)	Mortality Rate (%)	Morbidity Rate (%)	Median OS (mo)	OS 95% CI (mo)	PFS(95% CI) (mo)	DFS/RFS (95% CI) (mo)	Follow-up times (range) (mo)
HIPEC single arm studies
Alzahrani/ 2015/ Australia [41]	≈84	56	≈40	≈26	24	1.2	23.3	28	NR	NR	NR	NR
Beaujard/ 2000/ France [42]	NR	NR	NR	NR	NR	NR	NR	12	NR	NR	NR	NR
Bijelic/ 2008/ Australia [43]	≈94	≈56	≈44	≈23	17	NR	NR	30	NR	15	NR	Mean: 40.8 Median: 29.5
Braam/ 2014/ Australia [44]	NR	NR	NR	NR	6	NR	NR	14.9	NR	NR	11.4	26.2
Cao/ 2009/ Australia [45]	83.6	65.4	51.4	32.1	32.1	NR	NR	37.0	1-72	NR	NR	19 (1-72)
Cavaliere/ 2006/ Italy [46]	NR	NR	25.8	NR	NR	3.3	22.5	19	NR	NR	16	16
Ceelen/ 2014/ Belgium [47]	≈75 (NNT) ≈75 (NCA) ≈96 (NCB)	≈57 (NNT) ≈47 (NCA) ≈89 (NCB)	≈39 (NNT) ≈30 (NCA) ≈71 (NCB)	≈32 (NNT) ≈19 (NCA) NA (NCB)	≈25 (NNT) ≈13 (NCA)	NR	NR	27 (included APP) 24 (Right colon) 27 (Left colon) 35 (Rectal) 25 (NNT) 22 (NCA) 39 (NCB) 30 (AC) 22 (NAC)	20.8-33.2 (included APP) 10.3-37.7 (Right colon) 22.8-31.2 (Left colon) 4.9-65 (Rectum) 19.1-30.9 (NNT) 12.9-31.1 (NCA) 17.6-60.4 (NCB) 20.7-39.3 (AC) 14.2-29.8 (NAC)	NR	NR	18

Note: yr: year; SR: survival rate; mo: months; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival; DFS: disease-free survival; NA: not achieved; NR: not reported; PMP: pseudomyxoma peritonei; L-OHP: oxaliplatin; MMC: mitomycin; all: all tumors in researches; MVR: multivisceral resection group; NVR: No visceral resection group; APP: appendix; NNT: non-neoadjuvant therapy; NCA: neoadjuvant chemotherapy alone; NCB: neoadjuvant chemotherapy + bevacizumab; AC: adjuvant chemotherapy; NAC: non- adjuvant chemotherapy